Multidrug-resistant atypical variants of Shigella flexneri in China.
A total of 10,021 fecal samples were obtained from patients with diarrhea or dysentery at hospitals in 8 provinces within the eastern, southern, western, northern, and central regions of China: Liaoning, Shandong, Jiangsu, Guangdong, Gansu, Sichuan, Xinjiang, and Hebei Provinces. Samples were screened for the presence of Shigella spp. by using API 20E strips (bioMerieux, Marcy l'Etoile, France). Serotyping was performed by using 1) an antisera kit specific for all type- and group-factor antigens (Denka Seiken, Tokyo, Japan) and 2) a panel of monoclonal antibodies against S. flexneri (MASF; Reagensia AB, Stockholm, Sweden). Antimicrobial susceptibility testing was performed by the disk diffusion method as described (4). Genetic relationships were estimated by using multilocus sequence typing, as described (5), and pulsed-field gel electrophoresis (PFGE) (6).
Overall, 1,109 bacterial pathogens were identified. Shigella spp. isolates were the most prevalent, representing 273 (24.6%) of the total. Among the Shigella strains, 92 atypical strains, with 3 different serologic agglutination profiles, were identified (Table 1); 1 of these strains was initially identified as the previously described serotype 4c (7) because it agglutinated with monovalent antiIV type antisera and monovalent anti-7,8 group antisera. This serotype was also serologically indistinguishable from S. flexneri serotype X variant (SFxv), which was recently reported in China (8), because it reacted with MASF B-, MASF 7(8)-, and MASF IV-1 E1037-specific antibodies (see online Technical Appendix Table 1, wwwnc.cdc.gov/EID/article/19/7/11-1221-Techapp1. pdf). However, this serotype could not produce indole, whereas SFxv could. This atypical serotype was provisionally designated S. flexneri X variant (-:7,8, E1037), indole-negative variety. We isolated 73 isolates belonging to this atypical variant, which has become the most frequent serotype in China (Table 1). In 2008, the first 19 S. flexneri X variant (-:7,8, E1037) isolates were detected in Beijing; then in 2009, 26 were detected in Beijing, and in 2010, 23 were detected in Beijing, 3 in Jiangsu Province, and 2 in Shandong Province.
The second atypical serotype reacted with monovalent anti-IV type antisera but not the group-specific antisera, and it agglutinated with MASF B-specific and MASF IV-1 E1037-specific antibodies. The serotype was provisionally named S. flexneri untypeable variant (-:E1037). Only 2 isolates of this variant were identified in 2010: 1 was recovered from Beijing (9), and the other was recovered from Jiangsu Province.
The third atypical serotype was provisionally designated S. flexneri serotype 2 variant (II:3,4,7,8) because it could agglutinate with monovalent anti-II type antisera and monovalent anti-3,4 and anti-7,8 group antisera. It also reacted with type-specific antibody MASF II and group-specific antibodies MASF Y-5 and MASF 7,8 (online Technical Appendix Table 1). A total of, 17 isolates of serotype 2 variant (II:3,4,7,8) have been detected in Jiangsu Province: 10 in 2008, 4 in 2009, and 3 in 2010.
The atypical serotype strains were all multidrug resistant to ampicillin, ampicillin/sulbactam, chloramphenicol, nalidixic acid, and tetracycline; a total of 91.3% were also resistant to amoxicillin/clavulanic acid, and 84.8% were resistant to trimethoprim/sulfamethoxazole (Table 2; online Technical Appendix Table 2). The atypical strains also showed reduced susceptibility to fluoroquinolones and third-generation cephalosporins. Of the X variant (-:7,8, E1037), indole-negative variety strains, 82.2% were resistant to norfloxacin, 39.7% to ciprofloxacin, 21.9% to levofloxacin, and 13.7% to cefotaxime. Of the serotype 2 variant (II:3,4,7,8) strains, 29.4% were resistant to norfloxacin, 29.4% to ciprofloxacin, 17.6% to levofloxacin, and 17.6% to cefotaxime. The 2 S. flexneri untypeable variant (-:E1037) strains were also resistant to norfloxacin and ciprofloxacin. Furthermore, 6 of the X variant (-:7,8, E1037), indole-negative variety strains were also resistant to ciprofloxacin and cefotaxime.
Multilocus sequence typing identified all of the variant strains as a new sequence type (ST), ST100, which differs from ST18 at the lysP locus only (online Technical Appendix Figure). Other serotypes (e.g., 1a, 2a, 2b, and Y) were also identified as ST100. The 73 isolates of X variant (-:7,8, E1037), indole-negative variety were typed into 29 distinct pulse types (PTs) by PFGE analysis, and the 2 S. flexneri untypeable variant (-:E1037) isolates belonged to different PTs and had relatively low similarity (online Technical Appendix Figure). The 17 serotype 2 variant (II:3,4,7,8) isolates grouped into 17 PTs, showing high genetic diversity. Several serotype 2 variant (II:3,4,7,8) isolates had greater genetic distance from other serotype 2 isolates. In particular, PT70 had a genetic similarity of <65% with other serotype 2 variant (II:3,4,7,8) isolates.
Three varieties of S. flexneri serotypes, including 92 atypical strains, were identified in this study. The X variant (-:7,8, E1037), indole-negative variety displayed a serologic agglutination profile indistinguishable from that for SFxv, but the indole-negative variety had different biochemical reactions, more serious drug resistance, and different ST and PTs. All variant strains were identified as ST100, a new ST containing multiple other serotypes (e.g., 1a, 2a, 2b, and Y). This finding demonstrates that ST100 is the predominant ST circulating among different S. flexneri serotypes in China. Moreover, the 3 atypical varieties were also genetically distinct by PFGE analysis and showed a relatively high level of genetic diversity; thus, these S. flexneri varieties may have existed for a long time or experienced frequent genetic mutations.
The X variant (-:7,8, E1037), indole-negative variety serotype has supplanted serotype 2a and S. sonnei (3) and represents a new dominant S. flexneri serotype in China; serotype 2 variant (II:3,4,7,8) has become the fifth most common serotype of Shigella spp. in China. The variant strains were prevalent mainly in Beijing and in Jiangsu and Shandong Provinces; these provinces, located in the eastern and northern regions of China, have more developed economies and larger populations compared with the provinces in western China. Industrialization, trade, frequent movement of population, and environmental change can cause the shifting prevalence of diarrheal pathogens and lead to the dissemination of foodborne diseases worldwide (10,11). Therefore, the dynamic change in S. flexneri, especially the emergence of new serotypes, may be attributable to the economy and trade development or to human migration.
Of particular concern is that the atypical strains were completely resistant to several antimicrobial drugs used to treat shigellosis in China (12), and they showed reduced susceptibility to fluoroquinolones and third-generation cephalosporins. The World Health Organization has recommended ciprofloxacin as a first-line antimicrobial drug for shigellosis treatment (12), and third-generation cephalosporins are considered as alternative drug treatments (13). However, the S. flexneri resistance to ciprofloxacin and cefotaxime that we detected in this study was higher than previously reported in China (8,14); this finding raises serious questions regarding the effective treatment of shigellosis in the future.
In conclusion, 3 atypical S. flexneri serotypes with extensive multidrug resistance, distinct PTs, and a novel ST were identified in China. Continuous surveillance should be encouraged to determine the changing trends of these variants in geographic, temporal, phenotypic, and genotypic patterns. Such knowledge will improve our understanding of the actual level of disease and provide guidance for the prevention and control of shigellosis.
This work was funded by Mega-projects of Science and Technology Research of China (nos. 2012ZX10004215, 2013ZX10004607, 2011ZX10004001. and 2012ZX10004801), the National Natural Science Foundation of China (grant nos. 81202252, 81001267, and 31200942), and Beijing Science and Technology Nova program (no. 2010B067).
Dr Qiu is an associate professor at the Center for Infectious Disease Control, Institute of Disease Control and Prevention, Academy of Military Medical Sciences in Beijing. He specializes in the epidemiology and microbiology of infectious diseases.
(1.) World Health Organization. Diarrhoeal disease; fact sheet no. 330, April 2013 [cited 2013 Apr 12]. http://www.who.int/mediacentre/ factsheets/fs330/en/index.html
(2.) World Health Organization. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1 [cited 2013 Apr 12]. http://www.who.int/maternal_child_adolescent/ documents/9241592330/en/index.html
(3.) Wang XY, Tao F, Xiao D, Lee H, Deen J, Gong J, et al. Trend and disease burden of bacillary dysentery in China (1991-2000). Bull World Health Organ. 2006;84:561-8. http://dx.doi.org/10.2471/ BLT.05.023853
(4.) Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests; approved standard, 11th ed. CLSI document M02-A11. Wayne, PA: The Institute; 2012 [cited 2013 Apr 12]. http://antimicrobianos.com.ar/ATB/wp-content/ uploads/2012/11/01-CLSI-M02-A11-2012.pdf
(5.) EcMLST, a multilocus sequence typing database system for pathogenic E. coli. Version 1.2 [cited 2013 Apr 12]. http://www.shigatox.net/ecmlst/cgi-bin/index
(6.) Ribot EM, Fair MA, Gautom R, Cameron DN, Hunter SB, Swaminathan B, et al. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157:H7, Salmonella, and Shigella for PulseNet. Foodborne Pathog Dis. 2006;3:59-67. http://dx.doi.org/10.1089/fpd.2006.3.59
(7.) Pryamukhina NS, Khomenko NA. Suggestion to supplement Shigella flexneri classification scheme with the subserovar Shigella flexneri 4c: phenotypic characteristics of strains. J Clin Microbiol. 1988; 26: 1147-9.
(8.) Ye C, Lan R, Xia S, Zhang J, Sun Q, Zhang S, et al. Emergence of a new multidrug-resistant serotype X variant in an epidemic clone of Shigella flexneri. J Clin Microbiol. 2010;48:419-26.
(9.) Qiu S, Wang Z, Chen C, Liu N, Jia L, Liu W, et al. Emergence of a novel Shigella flexneri serotype 4s evolved from serotype X variant in China. J Clin Microbiol. 2011;49:1148-50. http://dx.doi. org/10.1128/JCM.01946-10
(10.) Galanis E, Lo Fo Wong DM, Patrick ME, Binsztein N, Cieslik A, Chalermchikit T, et al. Web-based surveillance and global Salmonella distribution, 2000-2002. Emerg Infect Dis. 2006;12:381-8. http://dx.doi.org/10.3201/eid1203.050854
(11.) Harris AM, Chowdhury F, Begum YA, Khan AI, Faruque AS, Svennerholm AM, et al. Shifting prevalence of major diarrheal pathogens in patients seeking hospital care during floods in 1998, 2004, and 2007 in Dhaka, Bangladesh. Am J Trop Med Hyg. 2008;79:708-14.
(12.) Pazhani GP, Niyogi SK, Singh AK, Sen B, Taneja N, Kundu M, et al. Molecular characterization of multidrug-resistant Shigella species isolated from epidemic and endemic cases of shigellosis in India. J Med Microbiol. 2008;57:856-63. http://dx.doi.org/10.1099/ jmm.0.2008/000521-0
(13.) Bhattacharya D, Purushottaman SA, Bhattacharjee H, Thamizhmani R, Sudharama SD, Manimunda SP, et al. Rapid emergence of thirdg-eneration cephalosporin resistance in Shigella sp. isolated in Andaman and Nicobar Islands, India. Microb Drug Resist. 2011 ;17:329-32. http://dx.doi.org/10.1089/mdr.2010.0084
(14.) von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med. 2006;3:e353. http://dx.doi.org/10.1371/journal.pmed.0030353
Shaofu Qiu,  Yong Wang,  Xuebin Xu,  Peng Li,  Rongzhang Hao,  Chaojie Yang,  Nan Liu,  Zhenjun Li,  Zhongqiang Wang,  Jian Wang,  Zhihao Wu,  Wenli Su,  Guang Yang,  Huiming Jin,  Ligui Wang,  Yansong Sun, Zhengan Yuan, Liuyu Huang, and Hongbin Song
Author affiliations: Academy of Military Medical Sciences, Beijing, China (S. Qiu, Y. Wang, P. Li, R. Hao, C. Yang, N. Liu, Z. Wang, J. Wang, Z. Wu, W. Su, G. Yang, L. Wang, Y. Sun, L. Huang, H. Song); Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China (X. Xu, H. Jin, Z. Yuan); and Chinese Center for Disease Control and Prevention, Beijing (Z. Li)
Address for correspondence: Hongbin Song, Institute of Disease Control and Prevention, Academy of Military Medical Sciences, 20 Dongda St, Fengtai District, Beijing 100071, China; email: firstname.lastname@example.org
Table 1. Distribution of different Shigella spp. in China during 2008-2010 and 1991-2000 Serotype 1991-2000 * May 2008- December 2010 No. (%) No. (%) isolates isolates S. flexneri 8,082 (86.2) 208 (76.2) 1a 272 (2.9) 9 (3.3) 1b 325 (3.5) 29 (10.6) 1c 15 (0.2) 0 2a 6,468 (69.0) 64 (23.4) 2b 152 (1.6) 3 (1.1) 3a 255 (2.7) 0 3b 57 (0.6) 0 3c 9 (0.1) 0 4 230 (2.5) 0 5 30 (0.3) 1 (0.4) 6 73 (0.8) 3 (1.1) x 70 (0.7) 5 (1.8) y 126 (1.3) 2 (0.7) X variant (-:7,8, E1037), 0 73 (26.7) indole-negative variety S. flexneri serotype 2 0 17 (6.2) variant (II:3,4,7,8) S. flexneri untypeable 0 2 (0.7) variant (-:E1037) S. sonnei 1,022 (10.9) 56 (20.5) S. dysenteriae 132 (1.4) 6 (2.2) S. boydii 139 (1.5) 3 (1.1) * Data are from (1). Table 2. Antimicrobial drug resistance profiles of variant serotypes of Shigella flexneri isolates recovered from patients with diarrhea, China, May 2008-December 2010 * Antimicrobial drug % Resistant isolates X variant (-:7,8,E1037), indole-negative variety, n = 73 R I S Ampicillin 100.0 0 0 Ampicillin/sulbactam 100.0 0 0 Chloramphenicol 100.0 0 0 Nalidixic acid 100.0 0 0 Tetracycline 100.0 0 0 Amoxicillin/clavulanic acid 91.8 5.5 2.7 Trimethoprim/sulfa 90.4 0 9.6 Norfloxacin 82.2 16.4 1.4 Ciprofloxacin 39.7 49.3 11.0 Levofloxacin 21.9 26.0 52.1 Cefotaxime 13.7 13.7 72.6 Gentamicin 6.8 0 93.2 Ceftazidime 5.5 2.7 91.8 Imipenem 2.7 0 97.3 Antimicrobial drug % Resistant isolates Serotype 2 variant (II:3,4,7,8), n = 17 R I S Ampicillin 100.0 0 0 Ampicillin/sulbactam 100.0 0 0 Chloramphenicol 100.0 0 0 Nalidixic acid 100.0 0 0 Tetracycline 100.0 0 0 Amoxicillin/clavulanic acid 88.2 0 11.8 Trimethoprim/sulfa 58.8 0 41.2 Norfloxacin 29.4 0 70.6 Ciprofloxacin 29.4 0 70.6 Levofloxacin 17.6 11.8 70.6 Cefotaxime 17.6 5.9 76.5 Gentamicin 5.9 0 94.1 Ceftazidime 0 0 100.0 Imipenem 0 0 100.0 Antimicrobial drug % Resistant isolates Untypeable variant (-:E1037), n = 2 R I S Ampicillin 100.0 0 0 Ampicillin/sulbactam 100.0 0 0 Chloramphenicol 100.0 0 0 Nalidixic acid 100.0 0 0 Tetracycline 100.0 0 0 Amoxicillin/clavulanic acid 100.0 0 0 Trimethoprim/sulfa 100.0 0 0 Norfloxacin 100.0 0 0 Ciprofloxacin 100.0 0 0 Levofloxacin 0 50.0 50.0 Cefotaxime 0 0 100.0 Gentamicin 0 0 100.0 Ceftazidime 0 0 100.0 Imipenem 0 0 100.0 * R, resistant; I, intermediate; S, susceptible.
|Printer friendly Cite/link Email Feedback|
|Author:||Qiu, Shaofu; Wang, Yong; Xu, Xuebin; Li, Peng; Hao, Rongzhang; Yang, Chaojie; Liu, Nan; Li, Zhenjun;|
|Publication:||Emerging Infectious Diseases|
|Date:||Jul 1, 2013|
|Previous Article:||Clinical findings for early human cases of influenza A(H7N9) virus infection, Shanghai, China.|
|Next Article:||MDR TB transmission, Singapore.|